


4<sup>TH</sup> SUMMIT ON  
**GASTROINTESTINAL  
MALIGNANCIES**

**SEPTEMBER 16-20, 2026**

**FAIRMONT HAMILTON PRINCESS  
BERMUDA**



# TABLE OF CONTENTS

**05** FACULTY

---

**09** BIOGRAPHIES

---

# FACULTY

## CHAIRS

### **Lipika Goyal, MD**

Associate Professor  
Stanford University  
Stanford, CA

### **Scott Kopetz, MD, PhD, FACP**

Professor  
Department of Gastrointestinal (GI) Medical Oncology  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, TX

### **Shubham Pant, MD, MBBS**

Professor, Department of Gastrointestinal (GI) Medical Oncology  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, TX

### **Manish A. Shah, MD**

Director, Gastrointestinal Oncology Program  
Weill Cornell Medicine  
Chief, Solid Tumor Service  
Co-Director, Center for Advanced Digestive Disease  
New York-Presbyterian  
New York, NY

## SPEAKERS

### **Jordi Rodon Ahnert, MD, PhD**

Professor, Department of Investigational Cancer Therapeutics  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, TX

### **Hani M. Babiker, MD**

Associate Professor of Medicine, Mayo Clinic College of  
Medicine and Science  
Consultant, Oncology  
Hepatopancreaticobiliary (HBP) Malignancies Program  
Early Cancer Therapeutics (ECTx)  
Division of Hematology and Oncology  
Mayo Clinic  
Jacksonville, FL

### **Emily K. Bergsland, MD**

Director, Center for Neuroendocrine Tumors  
Professor of Medicine  
UCSF Health  
San Francisco, CA

### **Anna Berkenblit, MD, MMSc**

Chief Scientific and Medical Officer  
PanCAN  
Boone, IA

### **Manoop S. Bhutani, MD, FASGE, FACP, AGAF**

Doctor Honoris Causa  
Professor of Medicine  
Walter H Wriston Distinguished Professor for Pancreatic Cancer  
Research  
Eminent Scientist of the Year 2008, World Scientist Forum  
Director of Endoscopic Research and Development  
Department of Gastroenterology, Hepatology and  
Nutrition-Unit 1466  
UT MD Anderson Cancer Center  
Houston, TX

### **Bruno Bockorny, MD, FACP**

Clinical Director, Phase 1 Oncology Program, Beth Israel Deaconess  
Medical Center  
Gastrointestinal Oncology, Dana-Farber Cancer Institute  
Assistant Professor of Medicine, Harvard Medical School  
Boston, MA

### **Patrick Boland, MD**

Associate Professor  
Associate Program Director, GI Medical Oncology  
Rutgers Cancer Institute  
New Brunswick, NJ

### **Dani Castillo, MD**

Assistant Clinical Professor, Department of  
Medical Oncology & Therapeutics Research  
City of Hope  
Duarte, CA

### **Michael Cecchini, MD**

Associate Professor of Medicine (Medical Oncology)  
Co-Director, Colorectal Program in the Center for  
Gastrointestinal Cancers  
Phase 1 Investigator, Yale Cancer Center  
Director, GI Clinical Research Team Yale Center for GI Cancers  
Yale School of Medicine  
New Haven, CT

### **Sreenivasa R. Chandana, MD, PhD**

Medical Oncologist  
The Cancer & Hematology Centers  
Grand Rapids, MI

### **William J. Chapin, MD, MSCE**

Assistant Professor, Medicine (Hematology-Oncology)  
Hospital of the University of Pennsylvania  
Philadelphia, PA

### **Saurin Chokshi, MD**

Section Chief – Clinical Practice, Assistant Professor  
The University of Tennessee Health Science Center  
Division of Hematology & Oncology  
Memphis, TN

### **James M. Cleary, MD, PhD**

Medical Oncologist, Dana-Farber Cancer Institute  
Director, Clinical Research, Division of Gastrointestinal Oncology  
Institute Physician  
Associate Professor of Medicine, Harvard Medical School  
Boston, MA

# FACULTY

## **Ashton A. Connor, MD, PhD**

Hepatobiliary and Pancreatic Surgery, Transplant Surgery  
Assistant Professor, Academic Institute at the Department of Surgery  
Houston Methodist  
Houston, TX

## **Jashodeep Datta, MD, FACS, FSSO**

The DiMare Family Endowed Chair in Immunotherapy  
Associate Professor of Surgery  
University of Miami Miller School of Medicine  
Assistant Director, Transdisciplinary Research  
Co-Leader, Gastrointestinal Oncology Service Line  
Sylvester Comprehensive Cancer Center  
Associate Director, Translational Research |  
Sylvester Pancreatic Cancer Research Institute  
Miami, FL

## **Channing J. Der, PhD**

Professor  
Department of Pharmacology  
UNC Lineberger Comprehensive Cancer Center and Member  
Curriculum in Genetics and Molecular Biology  
University of North Carolina at Chapel Hill  
Chapel Hill, NC

## **Marios Giannakis, MD, PhD**

Associate Professor of Medicine  
Harvard Medical School  
Associate Member, Broad Institute of MIT and Harvard  
Physician, Dana-Farber Cancer Institute  
Boston, MA

## **Sanjay Goel, MD, MS, FASCO**

Professor of Medicine  
Director, Phase I Therapeutics  
Co-Leader, Clinical Investigation and Precision  
Therapeutics Program  
Rutgers Cancer Institute  
New Brunswick, NJ

## **Tim F. Greten, MD**

CCR Deputy Director  
Deputy Chief, Thoracic and GI Malignancies Branch  
Senior Investigator  
Co-Director, NCI CCR Liver Cancer Program  
Center for Cancer Research  
National Cancer Institute, NIH  
Bethesda, MD

## **Aiwu R. He, MD, PhD**

Director of Hepatobiliary Cancers  
Director of Liver Transplant Oncology, Center for Liver Disease  
and Transplantation  
Professor of Medicine, Columbia University  
New York, NY

## **Aram F. Hezel, MD**

John and Ethel Heselden Professor  
Chief, Hematology/Oncology, Wilmot Cancer Institute  
Department of Medicine, Hematology/Oncology  
University of Rochester Medical Center  
Rochester, NY

## **Nicholas J. Hornstein, MD, PhD**

Assistant Professor  
Northwell Health Cancer Institute  
New York, NY

## **Z. Ian Hu, MD, PhD**

Assistant Professor  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

## **Dina Ioffe, MD**

Assistant Professor  
Division of Gastrointestinal Medical Oncology  
Fox Chase Cancer Center  
Philadelphia, PA

## **William R. Jarnagin, MD, FACS**

Hepatopancreatobiliary Surgeon  
Chief, Hepatobiliary Service  
Leslie Blumgart Chair in Surgery  
Memorial Sloan-Kettering Cancer Center  
New York, NY

## **Daniel Alexander King, MD, PhD**

Assistant Professor  
Institute of Cancer Research  
Feinstein Institutes for Medical Research  
Assistant Professor, Department of Internal Medicine  
Donald and Barbara Zucker School of Medicine at  
Hofstra/Northwell  
Lake Success, NY

## **Ignacio Garrido-Laguna, MD, PhD, MBA**

Chair, Department of Early Therapeutics Development  
Research Department Chair, Early Therapeutics Development  
Program Lead, Early Therapeutics Development  
Moffitt Cancer Center  
Tampa, FL

## **Mark Lewis, MD**

Director of Gastrointestinal Oncology  
Intermountain Healthcare  
Murray, UT

## **Andrew Lowy, MD, FACS**

Professor of Surgery, Step IX Chief  
Division of Surgical Oncology  
Rebecca and John Moores Cancer Center  
University of California  
San Diego, CA

## **Gulam A. Manji, MD**

Director of Gastrointestinal Oncology  
Director of Pancreas Translational Research  
Co-Director of The Pancreas Center  
Associate Professor of Medicine  
Columbia University Medical Center  
New York, NY

## **Sarbajit Mukherjee, MD**

Chief of GI Medical Oncology  
Miami Cancer Institute | Baptist Health South Florida  
Miami, FL

# FACULTY

## **Paul E. Oberstein, MD**

Associate Professor  
Service Chief, Gastrointestinal Medical Oncology Program  
Assistant Director, Pancreatic Cancer Center  
NYU Langone Health  
New York, NY

## **Haeseong Park, MD, MPH**

Director of Early Phase Trials, Gastrointestinal Cancer Center  
Dana Farber Cancer Institute  
Associate Professor of Medicine  
Harvard Medical School  
Boston, MA

## **Kanwal Raghav, MD, MBBS**

Professor, Gastrointestinal Medical Oncology  
Associate Vice President (AVP), Department of  
Ambulatory Medical Operations  
Executive Medical Director (EMD), Department of Ambulatory  
Treatment Centers (MDACC)  
The University of Texas MD Anderson Cancer Center  
Houston, TX

## **Devika Rao, MD, FACP**

Associate Attending Physician  
Memorial Sloan Kettering Cancer Center  
New York, NY

## **Matthew Reilley, MD**

Associate Professor of Medicine  
Director UVA Phase 1 Program  
Director GI Medical Oncology Research  
Division of Hematology/Oncology  
University of Virginia School of Medicine  
Charlottesville, VA

## **Anwaar Saeed, MD**

Associate Professor of Medicine  
Chief, Gastrointestinal Medical Oncology Program  
Director, Gastrointestinal Disease Center  
University of Pittsburgh Medical Center  
Pittsburgh, PA

## **John Paul Y.C. Shen, MD**

Assistant Professor  
Department of Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, TX

## **Despina Siolas, MD, PhD**

Assistant Professor of Medicine  
Weill Cornell Medical College, Cornell University  
New York, NY

## **Neeta Somaiah, MD**

Professor, Department of Sarcoma Medical Oncology  
Department Chair, Department of Sarcoma Medical Oncology,  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, TX

## **Jonathan Strosberg, MD**

Professor  
Moffitt Cancer Center  
Tampa, FL

## **Susanna Ulahannan, MD**

Associate Professor  
Director, Oklahoma TSET Phase 1 Program  
The University of Oklahoma  
Norman, OK

## **Jennifer B. Valerin, MD, PhD**

Assistant Professor, Medicine  
University of California, Irvine  
Orange, CA

## **Colin Weekes, MD, PhD**

Associate Professor, Medicine, Harvard Medical School  
Director, Medical Oncology Research for Pancreatic Cancer  
Director, Cancer Center Grand Rounds Program  
Massachusetts General Hospital  
Boston, MA

## **Benjamin Adam Weinberg, MD, FACP**

Associate Professor of Medicine  
Department of Medicine  
Division of Hematology and Oncology  
Lombardi Comprehensive Cancer Center (LCCC)  
Georgetown University Medical Center  
Washington, DC

## **Michael G. White, MD, MSc, FACS**

Associate Director of Research, Department of Colon &  
Rectal Surgery, Division of Surgery  
Clinical Trials Co-Lead, Department of Platform for Innovative  
Microbiome and Translational Research  
Assistant Professor, Department of Colon & Rectal Surgery  
The University of Texas MD Anderson Cancer Center  
Houston, TX

## **Jennifer Wu, MD**

Director, Bellevue Cancer Center  
Section Chief, Hematology Oncology  
Bellevue Medical Center  
Professor, Department of Medicine at NYU  
Grossman School of Medicine  
New York, NY

## **Zachary Yeung, MD**

Gastrointestinal Medical Oncologist  
Banner MD Anderson Cancer Center  
Sun City, AZ

## **Kenneth H. Yu, MD**

Associate Attending Physician  
Memorial Sloan Kettering Cancer Center  
New York, NY



## Lipika Goyal, MD

CHAIR

*Associate Professor  
Stanford University  
Stanford, CA*

Dr. Lipika Goyal is the Director of Gastrointestinal Oncology in the Stanford Cancer Institute and an Associate Professor in the Department of Medicine in the Stanford School of Medicine.

Dr. Goyal completed her B.A. in the Biological Basis of Behavior at the University of Pennsylvania and then with the support of a Rhodes Scholarship, pursued a Master of Philosophy in Development Studies at the University of Oxford. She then pursued medical training at Harvard Medical School, the Brigham and Woman's Hospital Internal Medicine Residency, and the Dana Farber/Harvard Cancer Center Hematology/Oncology Fellowship for her medical training. In 2013, she joined the faculty of the MGH Cancer Center as a medical oncologist in the Gastrointestinal Oncology group and later joined the Termeer Center for Target Therapy to pursue early phase drug development. In February 2023, she joined the faculty at Stanford.

Dr. Goyal was awarded the American Cancer Society Researcher of the Year Award in 2022 for her work on FGFR resistance in cholangiocarcinoma. In collaboration with a team of researchers, she is studying mechanisms of intrinsic and acquired resistance to FGFR inhibitors and novel approaches to delaying and overcoming resistance. Her clinical and translational research efforts broadly focus on the development of effective biomarkers and therapies for cholangiocarcinoma and hepatocellular carcinoma, and she serves as the principle investigator for numerous clinical trials to provide access to novel therapeutics for her patients.

She has served on the Hepatobiliary Cancers Panel of the National Comprehensive Cancer Network, the American Society of Clinical Oncology Education Committee, and the Steering Committee for National Cancer Institute Liver Cancer Moonshot Program. Her research is funded by grants from the National Institutes of Health, American Cancer Society, US Department of Defense, and the Cholangiocarcinoma Foundation.



## Scott Kopetz, MD, PhD, FACP

CHAIRS

*Professor  
Department of Gastrointestinal (GI) Medical Oncology  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, TX*

Dr. Scott Kopetz joined MD Anderson Cancer Center and is Professor and Deputy Chair in the Department of Gastrointestinal Medical Oncology. In the Cancer Medicine division, he is Co-Director of Cancer Biology. Within the institution, he is contact PI of our Gastrointestinal SPORE, leader of our CCSG GI Program, a leader of our Colorectal Cancer Moon Shot, serving as the Medical Director of our TRACTION platform, and the Associate Vice President for Translational Integration.

Dr. Kopetz is board-certified in internal medicine and in medical oncology. He has authored over 400 peer-reviewed articles in respected scientific journals such as New England Journal of Medicine, Journal of Clinical Oncology, Lancet, Lancet Oncology, JAMA, Cancer Discovery, and Nature Medicine. He is the principal investigator of several practice changing clinical trials, including trials for patients with BRAF mutated colorectal cancer that led to new standards of care. Dr. Kopetz leads the MD Anderson Gastrointestinal Cancer Center Program and is chair of the NCI Colon Cancer Task Force.



## Shubham Pant, MD, MBBS

*Professor, Department of Gastrointestinal (GI) Medical Oncology  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, TX*

Dr. Shubham Pant is a Professor in the Department of Gastrointestinal (GI) Medical Oncology at The University of Texas MD Anderson Cancer Center. Dr. Pant earned an MD from Maulana Azad Medical College. Dr. Pant completed his fellowship from the James Cancer Hospital/Solove Research Institute at the Ohio State University where he was elected Chief Fellow. He has previously served as the Director of Clinical Trials, Section of Hematology- and as Associate Director of the TSET Phase I Program at the University of Oklahoma. He was recipient of the Mai Eager Anderson Endowed Chair in Cancer Clinical Trials, was featured in “40 under 40” in Oklahoma magazine and has been voted by his peers as “America’s Top Doctors” (Castle Connolly) five years in a row. Dr. Pant is a member of GI-ICT Liaison Group at The University of Texas MD Anderson Cancer Center. He has an expertise in Targeted therapy and Immunotherapy and has co-authored numerous peer-review articles and is a Section Editor for the Handbook of Targeted Therapy and Immunotherapy.

Dr. Pant is a key opinion leader in the fields of Phase 1 (Early drug development) and GI Cancers including pancreatic, biliary, gall bladder and colorectal cancer. Nationally, he is a member of the Arm Selection Committee of Precision Promise, a Pancreatic Cancer Action Network (PanCan) initiative.



## Manish A. Shah, MD

CHAIR

*Director, Gastrointestinal Oncology Program  
Weill Cornell Medicine  
Chief, Solid Tumor Service  
Co-Director, Center for Advanced Digestive Disease  
New York-Presbyterian  
New York, NY*

Dr. Shah graduated from Johns Hopkins University in 1991 with a Bachelor's of Science degree in Biomedical Engineering, and from Harvard Medical School/MIT Health Sciences and Technology program in 1996, graduating magna cum laude, with a Medical Doctorate degree. He completed his Internal Medicine Residency training at Duke University Medical Center in 1999, and his Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in 2001, also serving as Chief Oncology Fellow. He is the recipient of several awards including the American Society of Clinical Oncology Young Investigator and Career Development Awards. He was recruited from Memorial Sloan Kettering Cancer Center to Direct the Gastrointestinal Oncology Program within the Division of Hematology and Medical Oncology and the Center for Advanced Digestive Care at Weill Cornell Medical College / New York-Presbyterian Hospital.

Dr. Shah is a national and international thought leader in drug development and the treatment of gastrointestinal malignancies. He is a distinguished peer-review funded investigator and has led several Phase I, II and III clinical trials in patients with advanced gastric cancer. Dr. Shah is also the Director of the Gastrointestinal Oncology Research Laboratory at Weill Cornell Medical College. His areas of translational research interests are in improving our understanding of cancers of the upper GI tract as well as hereditary gastrointestinal malignancies. He is interested in power of genomic evaluations of malignancy and how the environment and personal risks can impact the genetic causes of malignancy. He is a peer-reviewer for NIH and NCI research funding, and a reviewer for several high impact journals including the Journal of the American Medical Association, Journal of Clinical Oncology, Annals of Surgery, Annals of Surgical Oncology, Clinical Cancer Research and Gastroenterology. Dr. Shah is also the Editor for The Management of Complex Cases in Gastrointestinal Oncology Case Series for the Journal Of Gastrointestinal Oncology and the Series Editor for the Dx/Rx: Oncology Series published by Jones and Bartlett Publishers. He has authored several books including Dx/Rx: Upper Gastrointestinal Malignancies: Cancers of the Stomach and Esophagus, as well as 100 Questions and Answers about Stomach Cancer. He is a member of the American Society of Clinical Oncology (serving as a Cancer Education Committee Member), American Association of Cancer Research, and the American Gastroenterology Association. In addition, Dr. Shah is Chair of the Scientific Advisory Board for the DeGregorio Family Foundation for Stomach and Esophageal Cancer Education and Research.



## Jordi Rodon Ahnert, MD, PhD

---

*Professor, Department of Investigational Cancer Therapeutics  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, TX*

Dr. Jordi Rodón specializes in early drug development, biomarker discovery, personalized cancer medicine, and neuro-oncology. He received his medical and doctoral degrees from the Universitat Autònoma de Barcelona, and pursued post-graduate medical training at the Vall d'Hebron University Hospital. Dr. Rodón spent two years at the Advanced Drug Development program at the Institute for Drug Development (IDD) in San Antonio, Texas, and completed his training in drug development in ICT as a senior clinical research fellow. He joined the MD Anderson faculty in 2016 as an Associate Professor in the Department of Investigational Cancer Therapeutics (ICT) with a joint appointment in the Department of Genomic Medicine. Dr. Rodón also serves as Associate Medical Director for the Institute for Personalized Cancer Therapy and Clinical Co-Director of the Precision Oncology Decision Support Group. Over the course of his career, Dr. Rodón has been the principal or co-principal investigator on over 30 early phase clinical trials focusing on a range of advanced solid malignancies, partnering with leaders in industry including Novartis, Merck, Eli Lilly, Genentech, Sanofi, and others. With this, he has contributed to about 60 peer-reviewed publications detailing both trial results and basic research findings. Dr. Rodón's most significant contributions to the field include the development of PI3K, FGFR and TGFbeta inhibitors and multiple translational collaborations in those fields.



## Hani M. Babiker, MD

---

*Associate Professor of Medicine, Mayo Clinic College of Medicine and Science*  
*Consultant, Oncology*  
*Hepatopancreaticobiliary (HBP) Malignancies Program*  
*Early Cancer Therapeutics (ECTx)*  
*Division of Hematology and Oncology*  
*Mayo Clinic*  
*Jacksonville, FL*

Dr. Hanı Babiker is an Oncologist with board certification in Oncology and Hematology and initial certification in Internal Medicine and Geriatrics and Gerontology. He held academic appointments at the Translational Genomics Research Institute (TGen) and the University of Arizona. Prior to joining the Mayo Clinic, he was the Director of the Early Phase Clinical Trials Program and Co-Chair of DSMB at the University of Arizona Cancer Center. His research interests are in new drug development and in the treatment of gastrointestinal cancers with an emphasis on pancreatic cancer. He completed a drug development scholarship at the Virginia G Piper Cancer Center Clinical Trials/HonorHealth Research Institute in Scottsdale where he served as the principal investigator in many early phase clinical trials in solid tumors and participated in trials that led to drug approvals. He also has an interest both in developing new biomarkers and targeted therapies in pancreatic cancer. Dr. Babiker is currently the Associate Director, Clinical Research Operations Mayo Clinic Comprehensive Cancer Center, FL.

Dr. Babiker earned his M.D. with High Honors from Univerzita Komenskeho, Slovakia, and completed a residency in Internal Medicine and a fellowship in Geriatrics and Gerontology at Weill Cornell Medical College, New York Presbyterian Hospital. Dr. Babiker was an instructor in medicine at the Mayo Clinic College of Medicine in Phoenix. He also completed a Hematology and Medical Oncology fellowship at the University of Arizona where he also served as Chief Fellow. Dr. Babiker is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and the American College of Physicians. He has authored several abstracts and peer review manuscripts and has a passion for teaching and mentoring students and trainees.



## Emily K. Bergsland, MD

---

*Director, Center for Neuroendocrine Tumors*  
*Professor of Medicine*  
*UCSF Health*  
*San Francisco, CA*

Emily Bergsland, MD is a medical oncologist at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC) where she leads a clinical-translational research program focused on neuroendocrine neoplasms of all grades. Dr. Bergsland is a Professor of Medicine and Director of the Center for Neuroendocrine Tumors at UCSF. In addition, she serves as the Associate Director for Education for UCSF HDFCCC. She is a recognized leader in the field and previously served as the president of the North American Neuroendocrine Tumor Society (NANETS) and chair of the NET Task Force of the NCI Gastrointestinal Steering Committee. Dr. Bergsland currently chairs the Neuroendocrine and Adrenal Tumor Guidelines panel for the National Comprehensive Care Network.



## Anna Berkenblit, MD, MMSc

---

*Chief Scientific and Medical Officer*  
*PanCAN*  
*Boone, IA*

Dr. Anna Berkenblit is currently the Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network. She brings over two decades of experience in clinical development of novel anticancer therapies in the life science industry. Most recently, she served as chief medical officer at ImmunoGen, where she led the development of ImmunoGen's novel, wholly owned product candidates, including Elahere™, which recently received full approval by FDA for platinum-resistant ovarian cancer. Prior to that, Dr. Berkenblit was senior vice president, clinical development at H3 Biomedicine, and vice president, head of clinical research at AVEO Oncology. She also held positions of increasing responsibility at Wyeth/Pfizer, becoming vice president, neratinib asset team leader in the Pfizer Oncology Business Unit. Over the course of her career, she has led the clinical development of oncology products spanning early testing to registration trials.

Dr. Berkenblit earned an MD from Harvard Medical School, and an MMSc in the clinical investigator training program at Harvard/MIT Health Sciences & Technology. She completed her internship and residency at Brigham and Women's Hospital and went on to a hematology/oncology fellowship at Beth Israel Deaconess Medical Center (BIDMC). Prior to transitioning to industry, she led the Phase I oncology clinical trial program at BIDMC as part of the Dana-Farber/Harvard Cancer Center.



## **Manoop S. Bhutani, MD, FASGE, FACP, AGAF**

---

*Doctor Honoris Causa*

*Professor of Medicine*

*Walter H Wriston Distinguished Professor for Pancreatic Cancer Research*

*Eminent Scientist of the Year 2008, World Scientist Forum*

*Director of Endoscopic Research and Development*

*Department of Gastroenterology, Hepatology and Nutrition-Unit 1466*

*UT MD Anderson Cancer Center*

*Houston, TX*

Professor Bhutani is a Distinguished Professor and Director of Endoscopic Research and Development at MD Anderson Cancer Center which is consistently rated as the number one cancer center in the United States and worldwide. He published the world's first book on Interventional Endoscopic Ultrasound and has published many other books including Atlas of normal EUS anatomy and Textbook and Atlas of EUS pathology. His major research interests pertain to gastrointestinal endoscopy and endoscopic ultrasound including interventional endosonography, utility of endoscopic ultrasound for gastrointestinal cancers, role of endoscopic ultrasound in evaluation of pancreatic tumors and pancreatic masses, endoscopic ultrasound for cancer staging, experimental studies using endoscopic ultrasound and endoscopy for image guided targeted drug delivery and development of new imaging modalities for gastrointestinal tract cancers. He is regarded as a leading expert nationally and internationally in the field of gastrointestinal endoscopy, and specifically in the field of endoscopic ultrasonography. He has been invited for key note speeches and state-of-the art lectures in various national and international meetings. He has served as an expert invited speaker and/or live endoscopic workshop faculty around the world including the countries of Brazil, Spain, Germany, Romania, Israel, Egypt, Japan, Indonesia, South Korea, China, Belgium, Hungary, Colombia, Ecuador and India. He has more than >400 publications as original peer reviewed articles, editorials, invited reviews and other articles. He also has > 200 abstracts and scientific presentations at various national and international scientific meetings to his credit. He is a member of many editorial boards of various journals and Senior Associate Editor of the journal Endoscopic Ultrasound. In 2008 he received the Eminent Scientist of the Year Award in Endoscopy for his contributions to Endoscopic Ultrasound. In summary, Professor Bhutani is considered a leading expert and early pioneer in the world in the field of endoscopic ultrasonography.



## **Bruno Bockorny, MD, FACP**

---

*Clinical Director, Phase 1 Oncology Program, Beth Israel Deaconess Medical Center  
Gastrointestinal Oncology, Dana-Farber Cancer Institute  
Assistant Professor of Medicine, Harvard Medical School  
Boston, MA*

Bruno Bockorny, MD, is a medical oncologist and physician-scientist serving as Clinical Director of the Phase 1 Oncology Program at Beth Israel Deaconess Medical Center (BIDMC), currently transitioning to Dana-Farber Cancer Institute (DFCI). He holds a faculty appointment as Assistant Professor of Medicine at Harvard Medical School.

Dr. Bockorny's research program is centered on the clinical development of novel immunotherapies and targeted agents for gastrointestinal malignancies, with a particular focus on pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. He leads a portfolio of first-in-human and proof-of-concept studies and serves as Principal Investigator on more than a dozen clinical trials across the Harvard Cancer Center ecosystem. Dr. Bockorny completed his fellowship training in Hematology and Oncology at BIDMC and a postdoctoral fellowship in Molecular Biology at Dana-Farber Cancer Institute.



## **Patrick Boland, MD**

---

*Associate Professor  
Associate Program Director, GI Medical Oncology  
Rutgers Cancer Institute  
New Brunswick, NJ*

Dr. Patrick Boland is a medical oncologist specializing in gastrointestinal malignancies, with particular expertise in colorectal, small bowel, and anal cancers. He earned his medical degree from Jefferson Medical College, now Sidney Kimmel Medical College, in 2006, completed his internal medicine residency at Boston University Medical Center in 2009, and completed his oncology fellowship at Fox Chase Cancer Center in 2013.

Dr. Boland began his career at Roswell Park Cancer Institute, where he focused on the care of patients with lower gastrointestinal cancers. He has broad expertise in the treatment of cancers throughout the gastrointestinal tract and currently serves as Associate Program Director for GI Medical Oncology.

In addition to his clinical practice, Dr. Boland is deeply committed to clinical and translational research. He has developed and conducted multiple clinical trials and remains actively involved in the NCI National Clinical Trial Network and other research consortia. His work reflects a strong dedication to advancing cancer care through research, innovation, and patient-centered treatment.



## Dani Castillo, MD

---

*Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research  
City of Hope  
Duarte, CA*

Dr. Dani C. is an Assistant Clinical Professor at City of Hope specializing in gastrointestinal malignancies, with a focus on gastric and gastroesophageal cancers. Her work centers on biomarker-driven therapies and immuno-oncology, with an emphasis on improving outcomes in advanced disease.

She is actively involved in clinical trials and translational research integrating molecular profiling and tumor microenvironment analysis to advance precision oncology in GI cancers.



## Michael Cecchini, MD

---

*Associate Professor of Medicine (Medical Oncology)  
Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers  
Phase 1 Investigator, Yale Cancer Center  
Director, GI Clinical Research Team Yale Center for GI Cancers  
Yale School of Medicine  
New Haven, CT*

Dr. Michael Cecchini is a board-certified medical oncologist that specializes in the treatment of patients with advanced gastrointestinal (GI) cancers. His research is focused on early phase clinical trials to develop novel therapies that are biomarker driven for patients with advanced GI cancers. He is part of both the Phase 1 and GI Cancer teams at Yale and is Director of Clinical Research for the Yale Center for GI Cancers. Colorectal cancer represents a primary area of expertise within his broader GI oncology practice, with dedicated programmatic leadership as Co-Director of the Yale Colorectal Cancer Program. Furthermore, he performs translational research to better understand the relationship between DNA damage and the immune response for colorectal cancer to develop new biomarkers and treatment combinations for patients with advanced gastrointestinal cancers.



## **Sreenivasa R. Chandana, MD, PhD**

---

*Medical Oncologist  
The Cancer & Hematology Centers  
Grand Rapids, MI*

Dr. Sreenivasa R. Chandana specializes in developmental cancer therapeutics, including phase I, II, and III clinical trials, with a clinical focus on upper and lower gastrointestinal malignancies. Dr. Chandana received medical training at Guntur Medical College and earned a PhD from Wayne State University School of Medicine. Dr. Chandana completed a residency in internal medicine at McLaren Regional Medical Center/Michigan State University, followed by a fellowship in hematology/oncology at Michigan State University.



## **William J. Chapin, MD, MSCE**

---

*Assistant Professor, Medicine (Hematology-Oncology)  
Hospital of the University of Pennsylvania  
Philadelphia, PA*

William J. Chapin, MD, MSCE, is an Assistant Professor of Medicine in Hematology–Oncology at the Hospital of the University of Pennsylvania. He is a medical oncologist with clinical and academic involvement in the Penn Gastrointestinal Cancer Program and Penn Liver Cancer Program. Dr. Chapin earned his medical degree from the University of Chicago and completed both his residency and fellowship training at the University of Pennsylvania Health System.



## Saurin Chokshi, MD

---

*Section Chief – Clinical Practice, Assistant Professor  
The University of Tennessee Health Science Center  
Division of Hematology & Oncology  
Memphis, TN*

Saurin Chokshi, MD is a medical oncologist with a subspecialty focus on gastrointestinal malignancies. He earned his medical degree at University of Kentucky College of Medicine and did an internship in internal medicine at University of Texas Southern Medical Center. He completed a fellowship in hematology and medical oncology at Yale-New Haven Hospital, which is part of Yale School of Medicine; and participated in a clinical research training program at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland.

Along with seeing patients at Regional One Health as a medical oncologist, Dr. Chokshi is an assistant professor of hematology/oncology at University of Tennessee Health Science Center. He also serves on the medical advisory board for Bayer Virtual Roundtable. In addition to seeing patients in the clinic and in the hospital, his research interests are in early and late phase cancer clinical trials. He also oversees the Cancer Center's Clinical Trials Protocol Office.

His research has been published in numerous medical journals, including *Oncology* and *Cancer Journal*. During his career and education, he has been honored by the Society for Translational Oncology, American Association for the Advancement of Science, Arnold P. Gold Foundation and Joseph Collins Foundation. Dr. Chokshi is a member of the National Comprehensive Cancer Network panel for Management of Immunotherapy-Related Toxicity.



## James M. Cleary, MD, PhD

---

*Medical Oncologist, Dana-Farber Cancer Institute  
Director, Clinical Research, Division of Gastrointestinal Oncology  
Institute Physician  
Associate Professor of Medicine, Harvard Medical School  
Boston, MA*

Dr. James Cleary is a medical oncologist at the Dana-Farber Cancer Institute, specializing in the treatment of gastrointestinal cancers. He is an Associate Professor of Medicine at Harvard Medical School and co-directs the Pancreas and Biliary Center, as well as Clinical Research for Gastrointestinal Oncology, at Dana-Farber. His research focuses on identifying and developing novel therapeutic approaches for pancreatic and biliary tract malignancies.



## **Ashton A. Connor, MD, PhD**

---

*Hepatobiliary and Pancreatic Surgery, Transplant Surgery  
Assistant Professor, Academic Institute at the Department of Surgery  
Houston Methodist  
Houston, TX*

Ashton A. Connor, MD, PhD, serves as Assistant Professor of Academic Institute at the Department of Surgery. He earned his MD and PhD in genomic data science at the University of Toronto, where he also completed his general surgery residency. Following this, he completed a surgical fellowship in abdominal transplantation surgery at Duke University. Dr. Connor's research focuses on applying data science and genomics to oncology and immunology. Dr. Connor envisions a future where data science and tumor molecular profiling are deeply integrated into liver and pancreatic cancer care within the Houston Methodist Department of Surgery.



## Jashodeep Datta, MD, FACS, FSSO

---

*The DiMare Family Endowed Chair in Immunotherapy  
Associate Professor of Surgery , University of Miami Miller School of Medicine  
Assistant Director, Transdisciplinary Research  
Co-Leader, Gastrointestinal Oncology Service Line  
Sylvester Comprehensive Cancer Center  
Associate Director, Translational Research  
Sylvester Pancreatic Cancer Research Institute  
Miami, FL*

Dr. Jashodeep Datta is the DiMare Family Endowed Chair in Immunotherapy and an Associate Professor of Surgery at the University of Miami Miller School of Medicine, where he specializes in complex hepatobiliary and pancreatic surgical oncology. He also serves as Co-Director of the Liver-Directed Therapies Program at the NCI-designated Sylvester Comprehensive Cancer Center.

Dr. Datta leads a translational immuno-oncology research program funded by the NIH and Department of Defense, with a focus on myeloid immunobiology, tumor-stromal-immune crosstalk, and mechanisms of therapeutic resistance in pancreatic cancer. His laboratory develops innovative immunotherapy strategies targeting the suppressive myeloid compartment to improve outcomes in this challenging disease.

In addition to his research, Dr. Datta holds pivotal leadership roles at Sylvester: he is Co-Leader of the Gastrointestinal Oncology Service Line, responsible for advancing clinical care standards and overseeing the institution's portfolio of novel investigator-initiated and industry-sponsored trials for patients with GI cancers. He also serves as Assistant Director for Transdisciplinary Research, where he fosters collaborative science across the broader University of Miami ecosystem.

Dr. Datta's contributions have been recognized with numerous honors, including the Young Physician-Scientist Award from the American Society of Clinical Investigation and the Joan and Julius Jacobson Promising Investigator Award from the American College of Surgeons.



## Channing J. Der, PhD

---

*Professor*

*Department of Pharmacology*


*UNC Lineberger Comprehensive Cancer Center and Member*

*Curriculum in Genetics and Molecular Biology*

*University of North Carolina at Chapel Hill*

*Chapel Hill, NC*

Dr. Channing J. Der is Sarah Graham Kenan Distinguished Professor at the University of North Carolina at Chapel Hill. He received his PhD from the University of California, Irvine and completed his postdoctoral studies at Harvard Medical School and the Dana-Farber Cancer Institute. Since his initial discovery of RAS oncogenes in human cancer in 1982, his research has centered on the study of RAS oncoproteins in cancer. His research has been funded by grants from the National Cancer Institute (NCI), Department of Defense, Lustgarten Foundation, the Pancreatic Cancer Action Network, the American Cancer Society and the American Association of Cancer Research (AACR). He is a member of the NCI RAS Working Group and he served previously on the NCI Board of Scientific Counselors. He is currently a member of the Scientific and Medical Advisory Board of the Pancreatic Cancer Action Network and previously on the Scientific Advisory Board of the Lustgarten Foundation for Pancreatic Cancer Research. He has served on the scientific advisory board and as a consultant for numerous biotech and pharmaceutical companies developing inhibitors of RAS and RAS effector signaling. His honors include Fellow of the American Association for the Advancement of Science (AAAS), the recipient of an NCI Outstanding Investigator Award, the Battle Distinguished Cancer Research Award, the Mentorship Award for Lifetime Achievement, the University of California, Irvine Distinguished Alumnus Award, and the Einstein Berlin Institute of Health Visiting Fellow Award.



## Marios Giannakis, MD, PhD

---

*Associate Professor of Medicine*

*Harvard Medical School*

*Associate Member*

*Broad Institute of MIT and Harvard*

*Physician*

*Dana-Farber Cancer Institute*

*Boston, MA*

Dr. Marios Giannakis received his Honors Bachelor of Science degree from the University of Toronto and his M.D./Ph.D. in Molecular Genetics and Genomics at Washington University School of Medicine in Saint Louis. He was a medical resident at Brigham and Women's Hospital in Boston, a postdoctoral researcher at the Broad Institute of MIT and Harvard and hematology-oncology fellow at the Dana-Farber Cancer Institute

Dr. Giannakis is a physician-scientist at the Dana-Farber Cancer Institute, Associate Professor of Medicine at Harvard Medical School and Associate Member at the Broad Institute of MIT and Harvard. Dr. Giannakis has an active clinic caring for patients with gastrointestinal cancers and his laboratory studies the genomics, immunogenomics, molecular epidemiology and tumor microenvironment of colorectal cancer using patient-derived biospecimens and pre-clinical models towards novel preventive and therapeutic approaches for patients with this disease.



## Sanjay Goel, MD, MS, FASCO

---

*Professor of Medicine  
Director, Phase I Therapeutics  
Co-Leader, Clinical Investigation and Precision Therapeutics Program  
Rutgers Cancer Institute  
New Brunswick, NJ*

Sanjay Goel, MD, MS, FASCO, is an attending physician and a Professor of Medicine at Robert Wood Johnson Medical School. He serves as the Director of Phase I Therapeutics at Rutgers Cancer Institute. He has an interest in drug development of anti-cancer agents, and biomarkers of drug response, particularly in solid tumors and colorectal cancer. His work also includes outcomes of health in minority patients and health disparities. Dr. Goel has been the author or co-author on over 150 research publications, and owns a patent in EGFR targeted therapy.

He has been the recipient of the Advanced Clinical Research Award (ACRA) in colorectal cancer by the Conquer Cancer Foundation (CCF), of the American Society of Clinical Oncology (ASCO), and has been funded by the National Institutes of Health. He is active ASCO volunteer currently serving on the ASCO SEP Item Writing Task Force. He has also served as the track leader of the Scientific Program Committee in the “Developmental Therapeutics and Translational Research – Immunotherapy” track, of ASCO. He has been a grant reviewer on several NIH study sections and on the ASCO CCF Grant Review Committee. He has been an invited speaker at several national and international conferences.




## Tim F. Greten, MD

---

*CCR Deputy Director  
Deputy Chief, Thoracic and GI Malignancies Branch  
Senior Investigator  
Co-Director, NCI CCR Liver Cancer Program  
Center for Cancer Research  
National Cancer Institute, NIH  
Bethesda, MD*

Tim F. Greten, M.D., received his medical training at the Christian Albrechts University in Kiel, Germany. He did his internship in Munich followed by a 3-year postdoctoral fellowship at the Johns Hopkins University (Baltimore, Maryland), where he initiated his work in the field of tumor immunology. In 1999, Dr. Greten returned to Hannover Medical School, where he finished his training in Internal Medicine (2003), Medical Oncology (2004) and Gastroenterology (2007).

Dr. Greten is a physician-scientist who uses his medical expertise in Gastroenterology, Hepatology and Medical Oncology along with his research expertise in tumor immunology to develop novel treatments for patients with cancer. He heads a research team to study the tumor microenvironment in the liver in the context of Hepatocellular Carcinoma, Cholangiocarcinoma, and liver metastasis and studies how exogenous factors such as diet and the gut microbiome may affect immune responses in the liver. He also directs the GI Medical Oncology clinical team, that conducts clinical trials in patients with GI cancers. He and his team cover the entire research spectrum from basic tumor immunology and use of complex murine cancer models to the development and evaluation of new immunotherapies (including CAR T cells) for patients with gastrointestinal cancers. He conducts investigator-initiated first-in-human trials, phase I and II trials and has been one of the first investigators to test immune checkpoint inhibitors in patients with Hepatocellular carcinoma and Cholangiocarcinoma either alone or in combination with locoregional therapies.



## Aiwu R. He, MD, PhD

---

*Director of Hepatobiliary Cancers*

*Director of Liver Transplant Oncology, Center for Liver Disease and Transplantation*

*Professor of Medicine*

*Columbia University*

*New York, NY*

Aiwu Ruth He, M.D., Ph.D. is a Professor of Medicine at Columbia University Medical Center. She earned her M.D. from the Xiangya School of Medicine at Central South University and her Ph.D. in Biochemistry from East Carolina University's Brody School of Medicine. Dr. He completed postdoctoral training at the National Institutes of Health under the mentorship of Dr. Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

Dr. He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). During her early career under the mentorship of Dr. Lopa Mishra, she investigated the role of SPTBN1, an adaptor protein for SMAD3 in TGF- $\beta$  signaling, in the development of HCC. Her work demonstrated that the loss of SPTBN1 promotes oncoprotein expression, enhances tumorigenicity, and activates STAT3—a pathway known to drive HCC progression—highlighting STAT3 inhibition as a promising therapeutic target.

Dr. He leads numerous clinical trials focused on primary liver and biliary tract cancers. She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

Outside of her clinical duties, Dr. He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.



## Aram F. Hezel, MD

---

*John and Ethel Heselden Professor  
Chief, Hematology/Oncology, Wilmot Cancer Institute  
Department of Medicine, Hematology/Oncology  
University of Rochester Medical Center  
Rochester, NY*

Aram F. Hezel, MD, serves as Chief of the Division of Hematology and Oncology at the University of Rochester, where he is also a Professor in the Department of Medicine. He specializes in the care of patients with gastrointestinal cancers, with a particular focus on pancreatic and liver malignancies. His clinical work closely informs his research, which centers on the genetics, biology, and development of novel therapies for gastrointestinal cancers, including the design and conduct of clinical trials.

Dr. Hezel earned his MD from the SUNY at Buffalo School of Medicine & Biomedical Sciences. He completed his internship and residency training in internal medicine at Beth Israel Deaconess Medical Center, followed by a fellowship in medical oncology at Dana-Farber Cancer Institute.

Dr. Hezel is deeply committed to advancing physician-scientist training and has played an active role in mentoring oncology fellows, postdoctoral researchers, PhD candidates, and MD-PhD students at both institutional and national levels. As a clinician, investigator, and leader, he prioritizes fostering a supportive, inclusive, and collaborative environment within the academic and cancer research community.




## Nicholas J. Hornstein, MD, PhD

---

*Assistant Professor  
Northwell Health Cancer Institute  
New York, NY*

Nicholas Hornstein, MD, PhD, is a gastrointestinal medical oncologist and Assistant Professor at Northwell Health Cancer Institute. He specializes in colorectal cancer and liver metastases, leading clinical and translational research efforts to advance patient care. He has developed investigator-initiated trials, helped establish a hepatic artery infusion program, and collaborates with Cold Spring Harbor Laboratory on next-generation sequencing and biomarker discovery. Dr. Hornstein is the founder of TheGutOncLab, a collaborative platform focused on innovation in GI oncology. His work integrates AI-driven data platforms, including LUCID, to unlock insights from clinical data and improve trial design, precision medicine, and outcomes for patients.



## Z. Ian Hu, MD, PhD

---

*Assistant Professor  
The University of Texas MD Anderson Cancer Center  
Houston, Texas*

Dr. Z. Ian Hu, MD, PhD, is an Assistant Professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center. He is a physician-scientist dedicated to the care and study of gastrointestinal cancers.

After receiving his Bachelor of Science in Biology from Brown University, Dr. Hu earned both his Doctor of Medicine and Doctor of Philosophy degrees from Stony Brook University, where he built a strong foundation in both clinical medicine and scientific research. He went on to complete his internal medicine residency at Mount Sinai St. Luke's West in New York, followed by a fellowship in medical oncology at the National Cancer Institute, one of the nation's leading centers for cancer research and treatment.

Board-certified in internal medicine and medical oncology, Dr. Hu holds medical licenses in multiple states, reflecting a broad clinical scope and commitment to patient care. His clinical work and research focus are on hepatobiliary and colorectal cancers.

He is part of MD Anderson's multidisciplinary effort to advance cancer treatment through integrated patient care, research, and education. Dr. Hu combines rigorous academic training with specialized oncology expertise, contributing to MD Anderson's mission to improve outcomes for patients with complex cancers through innovation and evidence-based care, and ultimately, make cancer history.



## **Dina Ioffe, MD**

---

*Assistant Professor  
Division of Gastrointestinal Medical Oncology  
Fox Chase Cancer Center  
Philadelphia, PA*

Dr. Dina Ioffe is an Assistant Professor in the Division of Gastrointestinal Medical Oncology with a clinical and research focus on gastrointestinal malignancies, particularly hepatocellular carcinoma. She completed her MD at the University of Maryland School of Medicine, followed by internal medicine residency at the University of Maryland Medical Center and hematology/oncology fellowship at Fox Chase Cancer Center, where she also served as Chief Fellow. Her work spans translational research, geriatric oncology, and initiatives aimed at improving quality of care and addressing health disparities in cancer outcomes.



## **William R. Jarnagin, MD, FACS**

---

*Hepatopancreatobiliary Surgeon  
Chief, Hepatobiliary Service  
Leslie Blumgart Chair in Surgery  
Memorial Sloan-Kettering Cancer Center  
New York, NY*

William R. Jarnagin, MD, FACS, is Chief of the Hepatobiliary Service at Memorial Sloan Kettering Cancer Center and holds the Leslie Blumgart Chair in Surgery. He is a hepatopancreatobiliary surgeon with specialized expertise in surgery of the liver, pancreas, gallbladder, and bile ducts. In his role at MSK, Dr. Jarnagin oversees a team of board-certified surgeons who perform approximately 1,000 operations annually for hepatopancreatobiliary-related diseases, including pancreatic and liver resections, as well as palliative, diagnostic, and non-therapeutic procedures. His clinical approach emphasizes multidisciplinary collaboration to develop individualized treatment plans for each patient.

Dr. Jarnagin received his MD from Rush Medical College and completed a residency in general surgery at the University of California, San Francisco. He subsequently completed a fellowship in hepatobiliary surgery at Memorial Sloan Kettering Cancer Center and is board certified in surgery.



## Daniel Alexander King, MD, PhD

---

*Assistant Professor  
Institute of Cancer Research  
Feinstein Institutes for Medical Research  
Assistant Professor, Department of Internal Medicine  
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell  
Lake Success, NY*

Dr. Daniel King is a gastrointestinal medical oncologist and researcher specializing in pancreatic cancer based at Northwell Health and Cold Spring Harbor Laboratory. At Northwell Health, he serves as Director of Research and Development for the Northwell Health Cancer Institute's Center for Genomic Medicine. He leads a research group dedicated to the study of pancreatic cancer. He was the recipient of the Conquer Cancer Career Development Award for his project exploring the use of AI tools to navigate patients with early pancreatic cancer to care and onto research studies. He was also the recipient of the Robert A. Winn Career Development Award (Winn CDA) for his work studying methods to augment enrollment diversity onto clinical trials. His ongoing work in early detection and translational therapeutics are additional active areas of his research portfolio.



## Ignacio Garrido-Laguna, MD, PhD, MBA

---

*Chair, Department of Early Therapeutics Development  
Research Department Chair, Early Therapeutics Development  
Program Lead, Early Therapeutics Development  
Moffitt Cancer Center  
Tampa, FL*

Dr. Ignacio Garrido-Laguna is Chair of the Department of Early Therapeutics Development and serves as Research Department Chair and Program Lead for Early Therapeutics Development at Moffitt Cancer Center in Tampa, Florida. He is a medical oncologist with a strong focus on advancing innovative cancer therapies through early-phase clinical research.

Dr. Garrido-Laguna earned his medical degree from the School of Medicine at Universidad de Navarra in Pamplona, Spain. He completed his internship and residency in Internal Medicine–Medical Oncology at Hospital Universitario 12 de Octubre in Madrid, Spain, where he developed a strong foundation in clinical oncology.



## Mark Lewis, MD

---

*Director of Gastrointestinal Oncology  
Intermountain Healthcare  
Murray, UT*

Mark Lewis, MD, is Director of Gastrointestinal Oncology, Intermountain Healthcare. As a medical oncologist, Dr. Lewis specializes in cancers of the gastrointestinal tract and accessory organs. He has interests in young-onset cancers and hereditary cancer syndromes, shared decision-making, and patient-physician communication. As part of his clinical research activities, Dr. Lewis is active in the SWOG Cancer Research Network, a clinical trials cooperative group created by the National Cancer Institute; within SWOG he chairs the Adolescent and Young Adult (AYA) Oncology. A published researcher, Dr. Lewis has also served as a reviewer for multiple peer-reviewed journals. After attending Baylor College of Medicine, where he also served as resident and chief resident, Dr. Lewis completed a fellowship at Mayo Clinic. Dr. Lewis is Vice President of American Multiple Endocrine Neoplasia Support, serves on the communications committee for the North American Neuroendocrine Tumor Society, and is an active member of the American Society of Clinical Oncology.



## Andrew Lowy, MD, FACS

---

*Professor of Surgery, Step IX Chief  
Division of Surgical Oncology  
Rebecca and John Moores Cancer Center  
University of California  
San Diego, CA*

Dr. Andrew Lowy holds the Levine Family Chancellor's Distinguished Chair in Surgical Oncology and is Professor of Surgery, Director of Surgical Oncology and Associate Director of Moores Cancer Center at UC San Diego Health. He is a physician-scientist whose clinical and research primarily focuses on identifying and testing novel therapies for pancreatic and appendiceal cancer. His laboratory co-developed the first mouse model of human pancreatic cancer which has become the standard in the field, has been licensed to pharma and used by hundreds of labs worldwide. Dr. Lowy's research has led to the development and testing of novel therapies which have reached the clinic most recently a tumor penetrating peptide which is being tested in randomized Phase 2 trials.

Dr. Lowy has served in a number of national leadership roles including the NCI Clinical Trials and Translational Research Committee which advised on development of pancreatic cancer research priorities for the Recalcitrant Cancers Act, serving as vice-chair of the NCI Pancreatic Cancer Task Force, and chair from 2016-2021. He has served as co-leader of the SWOG pancreas cancer subcommittee since 2007. Dr. Lowy serves on the NCCN pancreatic cancer guidelines panel and on advisory boards for PANCAN, The Lustgarten Foundation, PANKIND, and The National Pancreas Foundation. Most recently, Dr. Lowy co-led the creation of the University of California Pancreatic Cancer Consortium.



## **Gulam A. Manji, MD**

---

*Director of Gastrointestinal Oncology  
Director of Pancreas Translational Research  
Co-Director of The Pancreas Center  
Associate Professor of Medicine  
Columbia University Medical Center  
New York, NY*

Dr. Gulam Manji, M.D., Ph.D. is an Associate Professor of Medicine at Columbia University Medical Center. Dr. Manji received his M.D. degree from Ross University School of Medicine in 2009 and completed his residency in internal medicine at Albany Medical College. He then completed his fellowship in Hematology/Oncology at NewYork-Presbyterian/Columbia, where his clinical focus was on the treatment of gastrointestinal malignancies, melanoma, and sarcoma under the mentorship of Dr. Gary Schwartz, Chief of Hematology and Oncology.

Dr. Manji conducts translational research with the overall goal to developing new treatments for cancer. His focus is in gastrointestinal malignancies, particularly pancreas adenocarcinoma, on which he is conducting preclinical combination immunotherapy studies on genetically engineered mice with pancreas cancer in the Olive laboratory at the Herbert Irving Comprehensive Cancer Center. The combination immunotherapy preclinical proposal received the Young Investigator Award from the American Society of Clinical Oncology-2015. The goal of these preclinical studies is to bring promising new therapies to the clinic in an early phase clinical trials Dr. Manji's research career in identifying new genes and their implication in disease has led to numerous key publications and an issued patent.

Dr. Manji cares for patients with gastrointestinal malignancies, with a particular focus on pancreatic and liver cancers, and sarcomas. He is the principal investigator of an investigator-initiated multicenter clinical trial that he wrote with Dr. Gary Schwartz in sarcoma and malignant peripheral nerve sheath tumors and is responsible for clinical trials conducted in liver, bile duct, gallbladder, and pancreas cancers at Columbia University Medical Center.



## Sarbajit Mukherjee, MD

---

*Chief of GI Medical Oncology  
Miami Cancer Institute | Baptist Health South Florida  
Miami, FL*

Dr. Sarbajit Mukherjee is the Chief of Gastrointestinal Medical Oncology at Miami Cancer Institute in Miami, FL. Dr. Mukherjee's current work focuses on novel clinical trials in GI malignancies. He has conducted multiple investigator-initiated clinical trials as a principal investigator. Dr. Mukherjee has received peer-reviewed grants from the Department of Defense, the National Comprehensive Cancer Network (NCCN), and the North American Neuroendocrine Tumor Society. He has presented at many national and international conferences and has been published in high-impact journals like Nature Medicine and the Journal of Clinical Oncology. He has served on grant review panels through the NIH (National Institutes of Health) and the US FDA.

Dr. Mukherjee co-chairs the GI clinical trial working group at the Hoosier Cancer Research Network. He also serves as a board member at the Esophageal Cancer Action Network. Dr. Mukherjee served the American Society of Clinical Oncology (ASCO) as a member of the Trainee Council Working Group, the Clinical Practice Guidelines Committee, and the Professional Development Committee. He also served on multiple guidelines panels for ASCO, NCCN, and the International Society of the Diseases of the Esophagus. He has received many awards, including membership in Alpha Omega Alpha Medical Honor Society and the Gold Humanism Honor Society. Dr. Mukherjee is invested in teaching and mentoring his junior colleagues and organizing and moderating educational and scientific meetings.



## Paul E. Oberstein, MD

---

*Associate Professor  
Service Chief, Gastrointestinal Medical Oncology Program  
Assistant Director, Pancreatic Cancer Center  
NYU Langone Health  
New York, NY*

Dr. Paul Oberstein focuses on cancers of the gastrointestinal tract, he treats people with various types of cancer, including stomach, pancreatic, colorectal, bile duct, and liver cancers. He works as the assistant director of the Pancreatic Cancer Center, part of NYU Langone's Perlmutter Cancer Center, where they focus exclusively on research and treatment for people who have pancreatic cancer.

His treatments are research-driven and he has participated in many clinical trials with the hope of providing our patients with newer and better treatment options, such as immunotherapy and novel chemotherapy combinations, along with better supportive and nutritional care. His research focus is on translational research, which means we collaborate with scientists who have made novel discoveries and help translate these discoveries into new treatments. He is also a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research and recipient of an ASCO Young Investigator Award for my work in clinical trials and a KL2 Career Development Award from the National Cancer Institute.



## Haeseong Park, MD, MPH

---

*Director of Early Phase Trials, Gastrointestinal Cancer Center  
Dana Farber Cancer Institute  
Associate Professor of Medicine  
Harvard Medical School  
Boston, MA*

Dr. Haeseong Park is the Director of Early Phase Trials at Gastrointestinal Cancer Center at Dana Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Her clinical focus is in gastric and esophageal cancers. Dr. Park aims to provide patients suffering from advanced cancers with novel, effective therapeutic options that will extend survival and improve quality of life. Her research focus is on developing molecularly informed, rational early phase clinical trials for GI malignancy. She is actively involved in developing, enrolling for, and analyzing several phase I/II clinical trials; while leading an NCI-supported randomized phase III trial to challenge the standard chemotherapy backbone in gastroesophageal cancer.



## Kanwal Raghav, MD, MBBS

---

*Professor, Gastrointestinal Medical Oncology  
Associate Vice President (AVP), Department of Ambulatory Medical Operations  
Executive Medical Director (EMD), Department of Ambulatory Treatment Centers (MDACC)  
The University of Texas MD Anderson Cancer Center  
Houston, TX*

Dr. Kanwal Raghav is a Professor in the Department of Gastrointestinal Medical Oncology (GIMO) at MD Anderson Cancer Center, Houston, TX (MDACC). His clinical and research efforts center on patients with colorectal cancer (CRC) with emphasis on cancer genomics and developmental therapeutics. He joined GIMO after completion of my fellowship in Hematology/Oncology in 2013 and since have led many clinical trials (targeted therapy and combined targeted and immune therapy) as principal investigator (PI) and authored multiple publications on tumor biology, therapeutic resistance, and cancer biomarkers. His research focuses on biomarker-based cancer therapy and genomically-driven clinical trials. Complementing his clinical research efforts, is his translational work on identifying putative predictive biomarkers for EGFR antibodies (HER2 amplification) using next-generation sequencing and ctDNA assays. Using one of the largest cohorts of HER2 amplified metastatic CRC (mCRC) his group validated the HER2 amplification as a predictive biomarker in mCRC. He has been an investigator on many HER2 trials such as the MyPathway HER2 targeting (trastuzumab + pertuzumab) study in mCRC, S1613, an NCI-NCTN randomized trial of cetuximab plus irinotecan (CETIRI) vs. trastuzumab plus pertuzumab (TP) in patients with refractory HER2 amplified metastatic colorectal cancer, DESTINY-CRC01 and CRC02 studies, and MOUNTAINNER-03 trial with trastuzumab and tucatinib.



## Devika Rao, MD, FACP

---


*Associate Attending Physician  
Memorial Sloan Kettering Cancer Center  
New York, NY*

Devika Rao, MD, FACP is an academic gastrointestinal medical oncologist and Medical Site Director within the Regional Care Network at Memorial Sloan Kettering (MSK) Cancer Center, an NCI-designated cancer center. She leads a high-volume clinical practice focused on complex gastrointestinal malignancies and holds key leadership roles in clinical operations, care delivery optimization, and health system strategy, including contributions to large-scale EMR implementation and workflow redesign.

Dr. Rao's academic work is focused on Hepatic Arterial Infusion Pump (HAIP) therapy for unresectable colorectal liver metastases. In collaboration with pioneers in the field, she has advanced the clinical application and dissemination of this specialized therapy. She developed a multidisciplinary educational curriculum for HAIP implementation and authored the first practical dosing guidelines, now widely used as a reference standard across institutions.

Dr. Rao is actively engaged in national education and leadership initiatives, including invited lectures, consortium collaborations, and advisory roles. She has established innovative training programs for medical students, fellows, and advanced practice providers, and serves as a mentor both nationally and internationally. Her additional contributions include work with the American Board of Internal Medicine and editorial leadership in oncology education.

Her work is dedicated to advancing gastrointestinal oncology through clinical innovation, education, and the development of scalable, patient-centered care models that improve access and outcomes across diverse healthcare settings.



## **Matthew Reilley, MD**

---

*Associate Professor of Medicine  
Director UVA Phase 1 Program  
Director GI Medical Oncology Research  
Division of Hematology/Oncology  
University of Virginia School of Medicine  
Charlottesville, VA*

Matthew Reilley, MD, is an associate professor of medicine at the University of Virginia School of Medicine. He manages patients with gastrointestinal cancers, including those in the stomach, esophagus, liver/bile ducts, pancreas, small intestines, colon, and rectum, as well as neuroendocrine tumors. Dr. Reilley's research is focused on developing new and effective therapies for patients with advanced cancer. He has led dozens of clinical trials and directs the phase 1 clinical trial program at the UVA Comprehensive Cancer Center.

Dr. Reilley earned his medical degree from Brown University. He completed his internal medicine residency at the University of Pennsylvania and a fellowship in hematology & medical oncology at The University of Texas MD Anderson Cancer Center, where he served as chief fellow. He has been recognized for his outstanding patient care and excellence in research. Dr. Reilley is board-certified in medical oncology and internal medicine.



## **Anwaar Saeed, MD**

---

*Associate Professor of Medicine  
Chief, Gastrointestinal Medical Oncology Program  
Director, Gastrointestinal Disease Center  
University of Pittsburgh Medical Center  
Pittsburgh, PA*

Dr. Anwaar Saeed is an Associate Professor of Medicine and the Chief of the Gastrointestinal (GI) Medical Oncology Program at the University of Pittsburgh. She is certified by the American Board of Internal Medicine and has completed a fellowship at the University of Kansas Medical Center. She earned her medical degree from Arabian Gulf University and completed her residency at Salmaniya Medical Complex. She is an active member and lead investigator in the Gastrointestinal (GI) Oncology program and the early phase developmental therapeutics program.



## John Paul Y.C. Shen, MD

---

*Assistant Professor  
Department of Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, TX*

Dr. John Paul Y.C. Shen is a physician-scientist with a scientific background in chemical biology and clinical training in Internal Medicine, Hematology, and Oncology. He is currently an Assistant Professor in the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center with a clinical practice focused on colon and appendix cancers. His long-term research goal is to better understand the cancer genome, and to leverage that understanding to better the delivery of chemotherapy. His immediate research goals include the discover of new synthetic lethal genetic relationships as a means to both repurpose already FDA approved drugs and also identify new chemotherapeutic drug targets. He is actively involved in several projects to identify genomic biomarkers to predict what specific patients will response to a given therapy. His research builds on my prior training in chemical biology and high-throughput screening, functional genomics and the creation of genetic interaction networks, as well as clinical oncology.

After completing medical school at Washington University, he matched into a combined Internal Medicine residency and Hematology-Oncology fellowship program at UCSD as part of the Physician-Scientist pathway. During the research portion of my fellowship, he joined the laboratory of Dr. Trey Ideker, an internationally recognized leader in the field of network and systems biology. The Ideker lab specializes in utilizing knowledge of network relationships to draw biological conclusions from large datasets as well as performing high-throughput genetic interaction experiments in both human and model organism systems.



## Despina Siolas, MD, PhD

---

*Assistant Professor of Medicine  
Weill Cornell Medical College, Cornell University  
New York, NY*

Dr. Despina Siolas received her Bachelor of Science with summa cum laude honors from St. John's University. She attended medical school at Stony Brook University, where she was awarded the prestigious E-Trade Financial Scholarship from the Hellenic Medical Society of New York. In addition to her MD degree, Dr. Siolas is the recipient of a Doctor of Philosophy in Genetics from the State University of New York at Stony Brook for studies she conducted in the lab of Greg Hannon PhD, Howard Hughes Medical Institute Professor, at Cold Spring Harbor Laboratory. She completed her internal medicine residency training and hematology/oncology fellowship at NYU Langone Health. In addition to treating patients, Dr. Siolas conducts research on cancer genes that influence the immune microenvironment using preclinical models of pancreatic cancer and colon cancer. She has authored numerous publications and has received a prestigious Mentored Clinical Scientist Research Career Development Award (K08) from the National Institute of Health. She is a member of the American Society for Clinical Oncology, the American Association for Cancer Research, and American Medical Association, and Hellenic Medical Society.



## Neeta Somaiah, MD

---

*Professor, Department of Sarcoma Medical Oncology  
Department Chair, Department of Sarcoma Medical Oncology, Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, TX*

Dr. Neeta Somaiah is a Professor in the Department of Sarcoma Medical Oncology at The University of Texas MD Anderson Cancer Center. She received her medical degree from Maulana Azad Medical College in New Delhi, India and has trained at St. John's Episcopal in New York, Drexel University Hospital and Fox Chase Cancer Center in Philadelphia, prior to joining MD Anderson Cancer Center.

Dr. Somaiah joined MD Anderson Cancer Center in 2012. She has over 16 years of sarcoma and clinical research experience. She is board certified in Medical Oncology. Her primary clinical and research focus is soft tissue sarcomas, specifically liposarcomas and GIST. She currently serves as the Principal Investigator of three investigator-initiated trials and nine cooperative group and industry-sponsored clinical trials at MD Anderson Cancer Center and has in depth knowledge with extensive experience in the design and execution of clinical trials. She also has multiple ongoing collaborations for translational research, both retrospective and prospective, that help improve the understanding of these rare group of diseases and explore the role of immunotherapy as a therapeutic avenue. Dr. Somaiah has been presented many honors for her expertise and contributions to science, including an Exceptional Women in Medicine award and is among the top 1% providers nationally (CG-CAHPS Patient Surveys).



## Jonathan Strosberg, MD

---

*Professor  
Moffitt Cancer Center  
Tampa, FL*

Dr. Jonathan Strosberg, MD, is a professor in the Department of Gastrointestinal Oncology at the Moffitt Cancer Center in Tampa, FL, specializing in the management of neuroendocrine malignancies. He is also section head of the Neuroendocrine Tumor Division and chair of the Gastrointestinal Department Research Program at the Moffitt Cancer Center.

Dr Strosberg has published more than 200 articles and book chapters on the diagnosis and management of neuroendocrine malignancies, including first-author publications in *The New England Journal of Medicine*, the *Journal of Clinical Oncology* and *The Lancet Oncology*.

He has served as president of the North American Neuroendocrine Tumor Society, and he serves on the National Comprehensive Cancer Network Neuroendocrine Guidelines Committee and on the National Cancer Institute Neuroendocrine Tumor Task Force.



## Susanna Ulahannan, MD

---

*Associate Professor  
Director, Oklahoma TSET Phase I Program  
The University of Oklahoma  
Norman, OK*

Dr. Susanna Ulahannan is an Associate Professor at the University of Oklahoma Health Sciences Center and serves as Director of the Oklahoma TSET Phase I Program. She specializes in gastrointestinal cancers and early-phase clinical trials. Dr. Ulahannan earned her Master of Medicine from Sahlgrenska Academy at the University of Gothenburg in Sweden, followed by residency training in Internal Medicine at the Johns Hopkins University/Sinai Hospital program in Baltimore, Maryland. She completed her fellowship in Hematology and Oncology at the National Cancer Institute/National Institutes of Health in Bethesda, Maryland. Through her clinical and research work, Dr. Ulahannan is dedicated to improving outcomes for patients with cancer by integrating cutting-edge clinical trials into patient care.



## Jennifer B. Valerin, MD, PhD

---

*Assistant Professor, Medicine  
University of California, Irvine  
Orange, CA*

Dr. Jennifer B. Valerin is a board-certified UCI Health medical oncologist who specializes in gastrointestinal malignancies and hereditary pancreatic cancer.

Dr. Valerin earned her medical degree from George Washington University School of Medicine and Health Sciences in Washington, D.C. She completed a residency in internal medicine UCLA, followed by a fellowship in hematology/oncology at MD Anderson Cancer Center in Houston, Texas.

She later received a PhD in cancer biology from the University of Texas at Houston/MD Anderson Cancer Center, where her research was focused on resistance mechanisms to inhibitors of the enzyme poly ADP ribose polymerase (PARP) in hereditary pancreatic cancer.

Dr. Valerin's research interests include gastrointestinal cancers, hereditary cancers, translational genomics and early-phase clinical trials. She is the author or co-author of numerous papers on studies of pancreatic and other cancers. She also received a Young Investigator Award from the American Society for Clinical Oncology (ASCO) and an award for her basic science research from the American Association for Cancer Research (AACR).



## Colin Weekes, MD, PhD

---

*Associate Professor, Medicine, Harvard Medical School  
Director, Medical Oncology Research for Pancreatic Cancer  
Director, Cancer Center Grand Rounds Program  
Massachusetts General Hospital  
Boston, MA*

Dr. Colin Weekes is an Associate Professor of Medicine at Harvard Medical School and Director of Medical Pancreas Cancer Research in the Division of Hematology/Oncology at Massachusetts General Hospital. Dr. Weekes focuses on clinical and translational research in pancreatic cancer, with an emphasis on integrating biologic principles, targeted therapies, and biomarkers of disease response into clinical trial development. In addition to pancreatic cancer research, Dr. [Name] is involved in early drug development for gastrointestinal malignancies. Dr. Weekes received an MD from the University of Nebraska College of Medicine, completed residency training at the University of Alabama Hospital, and pursued fellowship training at Johns Hopkins Hospital.



## Benjamin Adam Weinberg, MD, FACP

---

*Associate Professor of Medicine  
Department of Medicine  
Division of Hematology and Oncology  
Lombardi Comprehensive Cancer Center (LCCC)  
Georgetown University Medical Center  
Washington, DC*

Dr. Benjamin Weinberg is an Associate Professor of Medicine and Attending Physician specializing in gastrointestinal medical oncology. Dr. Weinberg is focused on developing new therapies for colorectal and pancreatic cancers by translating research from animal models into early phase clinical trials in humans. He also studies young patients with colorectal cancer and their microbiome in order to understand the dramatic rise in incidence of left-sided colon and rectal cancers in this population.

Dr. Weinberg obtained his undergraduate degree in biomedical science at the University of Pennsylvania in 2007 and his MD at the Keck School of Medicine of the University of Southern California in 2011. He completed his post-graduate medical training at MedStar Georgetown University Hospital with a residency in internal medicine in 2014 and a fellowship in hematology and oncology in 2017 where he served as the Chief Fellow from 2016 to 2017.



## Michael G. White, MD, MSc, FACS

---

*Associate Director of Research, Department of Colon & Rectal Surgery, Division of Surgery  
Clinical Trials Co-Lead, Department of Platform for Innovative Microbiome and Translational Research  
Assistant Professor, Department of Colon & Rectal Surgery  
The University of Texas MD Anderson Cancer Center  
Houston, TX*

Dr. Michael G. White, MD, MSc, FACS is a surgical oncologist in the Department of Colon & Rectal Surgery at The University of Texas MD Anderson Cancer Center. His clinical practice includes the surgical management of patients with peritoneal metastases from colorectal cancers. While his research aims study the role tumoral bacteria play in the progression of colorectal cancer and a tumor's response to chemotherapy and immunotherapies.



## Jennifer Wu, MD

---

*Director, Bellevue Cancer Center  
Section Chief, Hematology Oncology  
Bellevue Medical Center  
Professor, Department of Medicine at NYU Grossman School of Medicine  
New York, NY*

Dr. Jennifer Wu graduated from Albert Einstein College of Medicine in New York, completed internship at Montefiore Medical Center and obtained Hematology Oncology Fellowship from NYU School of Medicine in 2006. She joined the faculty of NYU Perlmutter Cancer Center in 2006, is currently an Associate Professor of Medicine at NYU School of Medicine. Her interest is in GI Oncology, with a focus in immune oncology, biomarker directed therapy and clinical trial inclusion of minority patients.




## Zachary Yeung, MD

---

*Gastrointestinal Medical Oncologist  
Banner MD Anderson Cancer Center  
Sun City, AZ*

Dr. Zachary Yeung is a board-certified medical oncologist specializing in gastrointestinal and neuroendocrine cancers. He completed his medical degree, internal medicine residency, and hematology/oncology fellowship at Baylor College of Medicine, where he developed a strong foundation in the management of complex malignancies. His clinical expertise includes colorectal, pancreatic, liver, esophageal, gastric, anal, and biliary tract cancers, as well as neuroendocrine tumors and rare endocrine neoplasms such as MEN1-associated tumors. Dr. Yeung is committed to delivering compassionate, personalized cancer care that empowers patients to make informed decisions throughout their treatment journey. His practice emphasizes evidence-based therapies, multidisciplinary collaboration, and individualized treatment planning to optimize outcomes and quality of life for patients facing gastrointestinal malignancies.



## Kenneth H. Yu, MD

---

*Associate Attending Physician  
Memorial Sloan Kettering Cancer Center  
New York, NY*

Dr. Kenneth H. Yu is an Associate Attending Physician at Memorial Sloan Kettering Cancer Center, specializing in the treatment of pancreatic, hepatobiliary, and other gastrointestinal cancers. His clinical and research work is focused on improving outcomes for patients with pancreatic cancer, with particular emphasis on the discovery and implementation of biomarkers for early diagnosis and the development of more effective therapeutic strategies. Dr. Yu's research program is supported by the National Cancer Institute/National Institutes of Health, the Lustgarten Foundation, and the Thompson Family Foundation. He earned his MD from Johns Hopkins University and an MSc from the University of Pennsylvania, where he also completed his residency in Internal Medicine and fellowship training in Hematology/Oncology at the Hospital of the University of Pennsylvania. Board certified in medical oncology, Dr. Yu integrates cutting-edge research with patient-centered care to advance the management of gastrointestinal malignancies.

JIWON LEE  
j.lee@davacro.com

GREGORY PYNES  
gpynes@davaonc.com

KARTIK VITTALA  
Kvittala@davaonc.com

DAVA ONCOLOGY  
5930 Royal Ln, Ste E, Dallas , TX 75230  
www.davaonc.com